Cancer Genetics, Inc. (CGIX) EPS Estimated At $-0.13

July 14, 2018 - By Kristin Houston

Cancer Genetics, Inc. (NASDAQ:CGIX) LogoInvestors sentiment increased to 1.11 in Q1 2018. Its up 0.20, from 0.91 in 2017Q4. It is positive, as 3 investors sold Cancer Genetics, Inc. shares while 6 reduced holdings. 6 funds opened positions while 4 raised stakes. 2.70 million shares or 2.75% less from 2.78 million shares in 2017Q4 were reported.
Hrt Fincl Ltd Liability Company holds 26,211 shares or 0.02% of its portfolio. New York-based Blackrock has invested 0% in Cancer Genetics, Inc. (NASDAQ:CGIX). Minnesota-based Perkins Cap Mngmt has invested 1.43% in Cancer Genetics, Inc. (NASDAQ:CGIX). Geode Cap Mngmt Ltd Limited Liability Company owns 87,279 shares. Northern stated it has 32,576 shares. Wells Fargo Com Mn stated it has 16,800 shares. Spark Inv Management Lc accumulated 11,600 shares. Morgan Stanley owns 16,169 shares or 0% of their US portfolio. Virtu Fincl Lc invested in 0% or 29,495 shares. Thompson Davis And holds 500 shares or 0% of its portfolio. Granahan Invest Incorporated Ma stated it has 235,502 shares. Barclays Public Ltd Co holds 0% or 454 shares. Renaissance Techs Ltd Com has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). Jacobs Levy Equity Management Inc has 0% invested in Cancer Genetics, Inc. (NASDAQ:CGIX). Dimensional Fund Advsr L P owns 19,866 shares for 0% of their portfolio.

Analysts expect Cancer Genetics, Inc. (NASDAQ:CGIX) to report $-0.13 EPS on August, 13.They anticipate $0.03 EPS change or 18.75 % from last quarter’s $-0.16 EPS. After having $-0.16 EPS previously, Cancer Genetics, Inc.’s analysts see -18.75 % EPS growth. The stock decreased 2.26% or $0.0202 during the last trading session, reaching $0.8754. About 124,683 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 74.25% since July 14, 2017 and is downtrending. It has underperformed by 86.82% the S&P500.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

Among 2 analysts covering Cancer Genetics (NASDAQ:CGIX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cancer Genetics had 5 analyst reports since January 16, 2018 according to SRatingsIntel. The stock of Cancer Genetics, Inc. (NASDAQ:CGIX) has “Buy” rating given on Tuesday, January 16 by H.C. Wainwright. H.C. Wainwright maintained Cancer Genetics, Inc. (NASDAQ:CGIX) on Tuesday, May 29 with “Buy” rating. The firm earned “Hold” rating on Tuesday, April 3 by Maxim Group. The stock has “Buy” rating by H.C. Wainwright on Wednesday, June 27. H.C. Wainwright maintained the shares of CGIX in report on Tuesday, February 6 with “Buy” rating.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $24.29 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

Cancer Genetics, Inc. (NASDAQ:CGIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.